Cochlear Ltd ADR CHEOY
Morningstar’s Analysis
1-Star Price
PREMIUM
5-Star Price
PREMIUM
Economic Moat
PREMIUM
There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible for overseeing the methodology that supports the quantitative fair value. As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.'s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities. For information regarding Conflicts of Interests, click here .
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile
Cochlear is the leading cochlear implant device manufacturer with around 60% global market share. Developed markets contribute 80% of revenues where cochlear implants are the standard of care for children with severe to profound hearing loss. The company is actively targeting the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remainder 20% of revenues. Products include cochlear and other ear implants, bone-anchored hearing aids (BAHA) and associated sound processors. In fiscal 2020 49% of revenue came from the Americas, 36% from EMEA and 17% from the Asia-Pacific segment.
Sydney, NSW, 2109, Australia